## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.4% below STRENGTH zone (4.0-10.0%); PEG 6.21 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($377.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. William Blair initiates Waters stock with Outperform rating, sees BD acquisition synergies**
- Source: Investing.com Nigeria | 20260105T120851 | Bullish | Relevance: 100%
- William Blair initiated coverage on Waters Corp. (NYSE:WAT) with an Outperform rating, citing better-than-expected fit and synergy potential from the BD Biosciences and Diagnostics Solutions portfolio acquisition. The firm projects mid-teens EPS compound annual growth and nearly $22 EPS by 2030 due to the transaction's benefits. This positive outlook follows strong Q3 2025 results for Waters, which exceeded analyst expectations and led to several analyst upgrades and price target increases.

**2. Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)**
- Source: Simply Wall Street | 20260104T120834 | Somewhat-Bullish | Relevance: 100%
- This article estimates the intrinsic value of Waters Corporation (NYSE: WAT) using a 2-stage Discounted Cash Flow (DCF) model. The analysis suggests a fair value of US$362 for Waters, indicating its current share price of US$382 is trading at similar levels. The valuation considers future cash flows, a terminal value calculation, and a discount rate of 7.9%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | William Blair | $0 | $0 | 0% |
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | William Blair | init | Outperform |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Volume divergence: price rising (+3.4% MRS) on declining volume (68% of avg) suggests distribution.
2. Valuation stretched: PEG 6.2x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 6.21 signals overvaluation risk, limited margin of safety. Forward P/E 27.6x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%, $439 target (+11%)). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.5B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.21 |
| Forward P/E | 27.6 |
| Current P/E | 30.1 |
| YoY Growth | 9.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.1% to 2.4% (+3.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.6pp (needs >4.0% for momentum thesis). MRS_5 at 2.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.35% (CS: 67) | Neutral |
| RSI_14 | 61.0 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.163x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $394.90
- **Stop Loss:** $377.80 (4.3% risk)
- **Target:** $412.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $19,745.00
- **Portfolio %:** 19.74%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*